LEGN

Legend Biotech (LEGN)

Legend Biotech Corporation

일자:

규정 관련뉴스

텍스트 검색:

정렬 기준:

규정 외 뉴스

검색 관련기사 보기:NASDAQ:LEGN

1 2 3 4 5 6 7 8 9 10 다음 >>

일자	시간	출처	헤드라인	심볼	기업
2024/11/14	22:46	Edgar (US Regulatory)	Form S-8 - Securities to be offered to employees in employee benefit plans	NASDAQ:LEGN	Legend Biotech Corporation
2024/11/12	21:03	Edgar (US Regulatory)	Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]	NASDAQ:LEGN	Legend Biotech Corporation
2024/11/12	21:00	GlobeNewswire Inc.	Legend Biotech Reports Third Quarter 2024 Results and Recent Highlights	NASDAQ:LEGN	Legend Biotech Corporation
2024/11/07	21:30	GlobeNewswire Inc.	Legend Biotech to Host Investor Event During the 66th American Society of Hematology (ASH) Annual Meeting and Exposition	NASDAQ:LEGN	Legend Biotech Corporation
2024/11/05	23:10	Edgar (US Regulatory)	Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]	NASDAQ:LEGN	Legend Biotech Corporation
2024/11/05	23:10	GlobeNewswire Inc.	Legend Biotech to Unveil Minimal Residual Disease Data from Landmark CARTITUDE-4 Trial in Multiple Myeloma	NASDAQ:LEGN	Legend Biotech Corporation
2024/11/04	21:30	GlobeNewswire Inc.	Legend Biotech Appoints Alan Bash as President of CARVYKTI®	NASDAQ:LEGN	Legend Biotech Corporation
2024/10/24	21:00	GlobeNewswire Inc.	Legend Biotech to Host Investor Conference Call on Third Quarter 2024 Results	NASDAQ:LEGN	Legend Biotech Corporation
2024/10/22	21:00	Edgar (US Regulatory)	Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]	NASDAQ:LEGN	Legend Biotech Corporation
2024/10/22	05:03	Edgar (US Regulatory)	Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]	NASDAQ:LEGN	Legend Biotech Corporation
2024/10/15	20:30	Edgar (US Regulatory)	Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]	NASDAQ:LEGN	Legend Biotech Corporation
2024/10/03	20:30	GlobeNewswire Inc.	Legend Biotech to Establish New, State-of-the-Art Cell Therapy Research and Development Facility in Philadelphia	NASDAQ:LEGN	Legend Biotech Corporation
2024/09/28	05:35	Edgar (US Regulatory)	Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]	NASDAQ:LEGN	Legend Biotech Corporation
2024/09/28	05:35	GlobeNewswire Inc.	CARVYKTI® is the First and Only Cell Therapy to Significantly Extend Overall Survival Compared to Standard of Care in Patients with Multiple Myeloma as Early as Second Line	NASDAQ:LEGN	Legend Biotech Corporation
2024/09/26	04:30	Edgar (US Regulatory)	Form 144 - Report of proposed sale of securities	NASDAQ:LEGN	Legend Biotech Corporation
2024/09/21	05:43	Edgar (US Regulatory)	Form 144 - Report of proposed sale of securities	NASDAQ:LEGN	Legend Biotech Corporation
2024/09/20	23:46	Edgar (US Regulatory)	Form 144 - Report of proposed sale of securities	NASDAQ:LEGN	Legend Biotech Corporation
2024/09/20	21:01	Edgar (US Regulatory)	Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]	NASDAQ:LEGN	Legend Biotech Corporation
2024/08/27	20:30	Edgar (US Regulatory)	Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]	NASDAQ:LEGN	Legend Biotech Corporation
2024/08/20	21:00	GlobeNewswire Inc.	Legend Biotech to Participate in the Morgan Stanley 22nd Annual Global Healthcare Conference	NASDAQ:LEGN	Legend Biotech Corporation
2024/08/09	20:01	Edgar (US Regulatory)	Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]	NASDAQ:LEGN	Legend Biotech Corporation
2024/08/09	20:00	GlobeNewswire Inc.	Legend Biotech Reports Second Quarter 2024 Results and Recent Highlights	NASDAQ:LEGN	Legend Biotech Corporation
2024/08/09	18:50	IH Market News	US Futures Climb Following Thursday’s Rally, Oil Prices Steady	NASDAQ:LEGN	Legend Biotech Corporation
2024/08/09	05:05	Edgar (US Regulatory)	Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]	NASDAQ:LEGN	Legend Biotech Corporation
2024/08/09	05:05	GlobeNewswire Inc.	Legend Biotech Appoints Peter Salovey, Ph.D., to its Board of Directors	NASDAQ:LEGN	Legend Biotech Corporation
2024/07/26	20:00	Edgar (US Regulatory)	Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]	NASDAQ:LEGN	Legend Biotech Corporation
2024/07/26	20:00	GlobeNewswire Inc.	Legend Biotech Announces Preliminary Results for the Six-Months Ended June 30, 2024	NASDAQ:LEGN	Legend Biotech Corporation
2024/07/17	20:30	Edgar (US Regulatory)	Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]	NASDAQ:LEGN	Legend Biotech Corporation
2024/07/10	21:00	GlobeNewswire Inc.	Legend Biotech to Host Investor Conference Call on Second Quarter 2024 Results	NASDAQ:LEGN	Legend Biotech Corporation
2024/07/02	21:00	GlobeNewswire Inc.	Legend Biotech Announces Positive Overall Survival Results of Landmark Phase 3 CARTITUDE-4 Trial in Multiple Myeloma	NASDAQ:LEGN	Legend Biotech Corporation